We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other small-cap stocks.
Fifteen small-cap stocks—predominantly under the technology sector—are taking center stage this year, boasting triple- to quadruple-digit performance in their share prices, thanks to the booming Artificial Intelligence sector.
In this article, we will dive into their performance and evaluate whether these stocks are poised to become the next big winners for your portfolio.
To come up with the 15 hottest small-cap stocks, we only considered companies with more than $3 million in trading volume and less than $2 billion in market capitalization.
Shares of Sangamo Therapeutics have been up by 164.71 percent in the past year, reflecting investor optimism, despite booking declines in its five-year performance.
Analysts posted a more bullish outlook for the company, setting a price target of $7 in the latest research last month.
In other news, the company recently terminated a partnership with Pfizer for their hemophilia A gene therapy co-development agreement. Following the termination, Sangamo now regains the rights to develop giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A.
Sangamo said it intends to explore all options to advance the program, including seeking a potential partner to collaborate with.
Overall SGMO ranks 7th on our list of the small-cap stocks poised to outperform in 2025. While we acknowledge the potential of SGMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as SGMO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。